BerGenBio ASA – Registration of reverse share split

Bergen, Norway, 3 June 2024. Reference is made to the stock exchange announcement made by BerGenBio ASA (the "Company") on 23 May 2024 regarding the Company's annual general meeting resolving a reverse share split of the Company's shares in the ratio 100:1. The reverse share split has today been registered with the Norwegian Register of Business Enterprises. Following such registration, the share capital of the Company is NOK 390,871,160 divided into 39,087,116 shares, each with a nominal value of NOK 10.

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Continuing Obligations pursuant to Oslo Rule Book II.